Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drug Development Research Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Drugs In Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Friedreich Ataxia, Cardiomyopathy and Mild Cognitive Impairment.
Frataxin Mitochondrial – Drugs In Development, 2021, outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)
- The report reviews Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics
Key Topics Covered:
Introduction
- Report Coverage
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Overview
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Companies Involved in Therapeutics Development
- AavantiBio Inc
- Adverum Biotechnologies Inc
- Anima Biotech Inc
- Biointaxis SL
- Cellivery Therapeutics Inc
- CRISPR Therapeutics AG
- Design Therapeutics Inc
- Fratagene Therapeutics Srl
- Fulcrum Therapeutics Inc
- Jupiter Orphan Therapeutics Inc
- Lacerta Therapeutics Inc
- Larimar Therapeutics Inc
- Novartis Gene Therapies
- PTC Therapeutics Inc
- Voyager Therapeutics Inc
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Drug Profiles
- ADVM-063 – Drug Profile
- AVXS-401 – Drug Profile
- CTI-1601 – Drug Profile
- CV-14 – Drug Profile
- etravirine – Drug Profile
- Gene Therapy to Activate Frataxin for Friedreich Ataxia – Drug Profile
- Gene Therapy to Activate Frataxin Mitochondrial for Friedreich’s Ataxia – Drug Profile
- JOT-101 – Drug Profile
- PTC-FA – Drug Profile
- Recombinant Proteins to Replace Frataxin Mitochondrial for Friedreich Ataxia – Drug Profile
- Small Molecule to Activate Frataxin for Friedreich Ataxia – Drug Profile
- Synthetic Peptide to Activate Frataxin for Friedreich Ataxia – Drug Profile
- VYFXN-01 – Drug Profile
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Dormant Products
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) – Product Development Milestones
Featured News & Press Releases
- May 25, 2021: Larimar Therapeutics reports FDA clinical hold on CTI-1601 and termination of recently announced private placement financing
- May 20, 2021: Larimar Therapeutics receives European Medicines Agency Priority Medicines (PRIME) designation for CTI-1601 in Friedreich’s ataxia
- May 11, 2021: Larimar Therapeutics reports positive topline phase 1 clinical trial data showing dose-dependent increases in frataxin levels in patients with Friedreich’s Ataxia
- Dec 08, 2020: Larimar Therapeutics announces completion of dosing of the single ascending dose clinical trial in Friedreich’s Ataxia patients and provides program update
- Jul 28, 2020: Larimar Therapeutics announces positive opinion on Orphan Drug Designation received from the European Medicines Agency for CTI-1601 for the treatment of Friedreich’s Ataxia
- Jul 20, 2020: Larimar Therapeutics announces dosing of patients in third cohort of phase 1 SAD trial of CTI-1601 for treatment of Friedreich’s ataxia
- Jan 13, 2020: MDA awards venture philanthropy funding of more than $1M to AavantiBio to develop gene-targeting therapy for Friedreich’s Ataxia
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/43bm0o
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
